| Title: | Real-world data linked to genetics and biomarkers to triangulate the evidence on the risk-benefit of medical products |
| Lead Institution: | University of Oxford |
| Principal investigator: |
Application 98358
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
About
It is crucial to figure out which drugs are effective and what side effects they might have. Most of the evidence depends on using observational data, which has well-known limitations such as confounders, defined as those variables that influence the outcome but are unmeasured or unknown, or reverse causality, in which we cannot determine whether the exposure affects the outcome or if it is backwards. Also, gaps are apparent in utilising large-scale data in UK Biobank with experts in pharmacogenetics and pharmacoepidemiologist working separately. Integrating disease phenotypes and genotypes will unleash the unimaginable potentials of the UK Biobank, but many theoretical and practical challenges remain ahead, requiring interdisciplinary efforts to conquer. We proposed triangulating evidence for a specific scientific question, leveraging in-depth genetic and health information and incorporating different research approaches. We, therefore, can be more confident with the findings derived from diverse methods pointing to the same conclusion. In this project, we will perform large-scale, cutting-edge and bespoke observational studies about medical products through robustly managing, standardizing, documenting and analysing comprehensive multiple-layer UK Biobank data, with a desire to engage in collaborative and multidisciplinary science. This research is in the public interest because it can provide better information for decision-makers, doctors, researchers, patients and the general population on the safety and effectiveness of medicines. The project duration plans to take at least 36 months.1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 13255 | Genome-wide association studies of COVID-19 vaccine seroconversion and breakthrough outcomes in UK Biobank | Marta Alcalde-Herraiz (+5) | 2024 | Nature Communications |
Enabling scientific discoveries that improve human health